Publication

118

Keunok Jung , Deok-Han Ko , Jeong-Yun Jang, Young Rong Kim, Jung Yeon Heo, Yong-Sung Kim*

 (2024)

Harnessing SARS-CoV-2-specific CD8+ T cells to kill target tumor cells for cancer immunotherapy. 

Cancer communications. 2024. January. 44:173-177.

(, Equal contribution)

117

Jun-Ho Kim, Dae-Seong Kim, Hae-Sim Park, and Yong-Sung Kim* (2023)

Engineering bispecific T-cell engagers to deplete eosinophils for the treatment of severe eosinophilic asthma. 

Clinical Immunology. 2023. October. 255:109755.

116

Sei-Yong Jun, Dae-Seong Kim, Yong-Sung Kim* (2022)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity.

International Journal of Molecular Sciences, 2022. December 13. 23(24), 15820.

115

Keunok Jung, Sojung Yoo, Jung-Eun Kim, Wook Kim and Yong-Sung Kim* (2022)

Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy.

Frontiers in Immunology, 2022. October 27. 13:1034774.

(, Equal contribution)

114

Seong-Wook Park, Da-Som Lee, and Yong-Sung Kim* (2022)

Engineering a U-box of E3 ligase E4B through yeast surface display-based functional screening generates a variant with enhanced ubiquitin ligase activity.

Biochemical and Biophysical Research Communications, 2022 July 5, 612:147-153.

113

Du-San Baek, Seong-Wook Park, Cynthia Adams, Dimiter S Dimitrov, Yong-Sung Kim* (2022)

Yeast Mating as a Tool for Highly Effective Discovery and Engineering of Antibodies via Display Methodologies.

Methods Mol Biol., 2022. 2491:313-333.

112

Keunok Jung, Min-Jeong Son, Se-Young Lee, Jeong-Ah Kim, Deok-Han Ko, Sojung Yoo, Chul-Ho Kim and Yong-Sung Kim* (2022)

Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8+ T cells for cancer immunotherapy.

Molecular Cancer, 2022. 21:102.

111

Ji Eun Lee, Min Gyu Woo, Kyung Hee Jung, Yeo Wool Kang, Seung-Min Shin, Mi Kwon Son, Zhenghuan Fang, Hong Hua Yan, Jung Hee Park, Young-Chan Yoon, Yong-Sung Kim and Soon-Sun Hong* (2022)

Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor on Pancreatic Cancer.

Biomolecules & Therapeutics, 2022 May 1;30(3):274-283.

110

Sua Lee, Shina Jang, Jihoon Kang, Soo Bin Park, Young Woo Han, Hyemi Nam, Munkyoung Kim, Jeewon Lee, Ki Joon Cho, Jeonghun Kim, Miyoung Oh, Jihye Ryu, Jong Hyeon Seok, Yunhwa Kim, Jee-Boong Lee, Man-Seong Park, Yong-Sung Kim, Hosun Park, Dong-Sik Kim* (2021)

MG1141A as a highly potent monoclonal neutralizing antibody against SARS-CoV-2 variants.

Frontiers in Immunology, 2021. November 18. 12:778829.

109

Seong-Wook Park, Sei-Yong Jun, Ji-Sun Kim, Yong-Sung Kim* (2021)

Engineering of an EpCAM-targeting cyclic peptide to improve the EpCAM-mediated cellular internalization and tumor accumulation of a peptide-fused antibody.

Biochemical and Biophysical Research Communications, 2021 October 8, 573:35-41.

108

Ji Eun Lee, Yeo Wool Kang, Kyung Hee Jung, Mi Kwon Son, Seung-Min Shin, Ji-Sun Kim, Soo Jung Kim, Zhenghuan Fang, Hong Hua Yan, Jung Hee Park, Young-Chan Yoon, Boreum Han, Min Ji Cheon, Min Gyu Woo, Myung Sung Seo, Joo Han Lim, Yong-Sung Kim*, Soon-Sun Hong* (2021)

Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.

Cancer Letters, 2021 June 1, 507:97-111.

107

Se-Young Lee, Deok-Han Ko, Min-Jeong Son, Jeong-Ah Kim, Keunok Jung, Yong-Sung Kim* (2021)

Affinity Maturation of a T-Cell Receptor-Like Antibody Specific for a Cytomegalovirus pp65-Derived Peptide Presented by HLA-A*02:01.

International Journal of Molecular Sciences, 2021 February, 22(5), 2349.

(, Equal contribution)

106

Jung-Eun Kim, Dong-Hyun Lee, Keunok Jung, Eun-Ji Kim, Youngwoo Choi, Hae-Sim Park*, Yong-Sung Kim* (2021)

Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.

Frontiers in Immunology, 2021. January 11:593748.

(, Equal contribution)

105

Jong-Hee Ko, Hyuk-Sang Kwon, Bomin Kim, Gihong Min, Chorong Shin, Seok-Woo Yang, Seong Wook Lee, Youngmin Lee, Dahae Hong, Yong-Sung Kim* (2020)

Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076).

Biomolecules, 2020. Jun 17;10(6):919.

104

Seung-Min Shin, Ji-Sun Kim, Seong-Wook Park, Sei-Yong Jun, Hye-Jin Kweon, Dong-Ki Choi, Dakeun Lee, Yong Beom Cho, Yong-Sung Kim* (2020)

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth.

Science Advances, 2020 January, 6(3):eaay2174.

(, Equal contribution)

103

Ji-Sun Kim, Sei-Yong Jun, and Yong-Sung Kim* (2020)

Critical issues in the development of immunotoxins for anticancer therapy.

Journal of Pharmaceutical Sciences, 2020 January, 109(1):104-115.

102

Keunok Jung, Jeong-Ah Kim, Ye-Jin Kim, Hyun Woo Lee, Chul-Ho Kim,*, Seokjin Haam* and Yong-Sung Kim* (2020)

A neuropilin-1 antagonist exerts anti-tumor immunity by inhibiting the suppressive function of intratumoral regulatory T cells.

Cancer Immunology Research, 2020 January, 8(1):46–56.

101

Ye-Jin Kim, Du-San Baek, Seyoung Lee, Daechan Park, Han Na Kang, Byoung Chul Cho*, and Yong-Sung Kim* (2019) 

Dual-targeting of EGFR and Neuropilin-1 Attenuates Resistance to EGFR-targeted Antibody Therapy in KRAS-mutant Non-Small Cell Lung Cancer.

Cancer Letters, 2019 December 1, 466:23-34.